Cyclerion Therapeutics (CYCN) Stock Analysis

What Cyclerion Therapeutics does

Cyclerion Therapeutics, Inc. operates as a biopharmaceutical company in the clinical development phase, concentrating on the discovery, advancement, and commercialization of therapeutic agents for debilitating central nervous system (CNS) disorders. Their leading experimental compound, CY6463, is a soluble guanylate cyclase (sGC) stimulator designed to cross the blood-brain barrier. It is presently in Phase IIa clinical assessments for managing mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes (MELAS), as well as Alzheimer's disease with vascular involvement. Concurrently, CY6463 is undergoing Phase 1 trials for treating schizophrenia in adult populations. The company's research portfolio also features other promising candidates: Praliciguat, an orally administered systemic sGC stimulator, is in Phase II studies targeting resistant hypertension and diabetic nephropathy. Olinciguat, another sGC stimulator designed for oral intake with a vascular focus, is progressing through Phase II trials for sickle cell disease. Moreover, CY3018 is under development to address a range of CNS ailments. Cyclerion holds a licensing agreement with Akebia Therapeutics, Inc., covering the entire lifecycle from development and manufacturing to medical affairs and commercialization for certain pharmaceutical compounds and related products. The company was founded in 2018 and has its principal place of business in Cambridge, Massachusetts.

Key metrics

ETFs linked to CYCN

Broad-market and Healthcare sector ETFs an investor holding Cyclerion Therapeutics is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how CYCN fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Similar companies

Frequently asked questions

What is the ticker symbol for Cyclerion Therapeutics?

Cyclerion Therapeutics trades under the ticker CYCN on NASDAQ.

Which exchange is CYCN listed on?

CYCN is listed on NASDAQ.

What sector does Cyclerion Therapeutics operate in?

Cyclerion Therapeutics is classified in the Healthcare sector (Biotechnology industry).

How can PortView help analyze CYCN in a portfolio?

PortView shows CYCN's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.